Vascularized Human Cardiac Organoids Reveal Endothelial-Cardiomyocyte Crosstalk and Mechanisms of Carfilzomib-Induced Cardiotoxicity

This study generates vascularized human cardiac organoids that exhibit enhanced cardiomyocyte maturation and bidirectional endothelial-cardiomyocyte crosstalk, thereby providing a physiologically faithful model to uncover the ER stress and inflammatory mechanisms underlying carfilzomib-induced cardiotoxicity.

The Gist

Imagine trying to study how a human heart works, or why a specific cancer drug might hurt the heart, but you only have a tiny, flat piece of paper to do it on. That's essentially what scientists have been doing for years with "heart organoids" (miniature hearts grown in a lab). They are great, but they lack one crucial thing: blood vessels.

Without blood vessels, these mini-hearts are like a city without roads. The buildings (heart cells) in the middle can't get fresh supplies (oxygen and nutrients) or take out the trash (waste), so they start to die. Worse, because they aren't connected to a "circulatory system," they don't grow up to be fully mature, adult-like heart cells. They stay stuck in a baby state.

This paper introduces a breakthrough: Vascularized Human Cardiac Organoids (vhCOs). Think of this as building a mini-heart city with a fully functional highway system built right into the neighborhood.

Here is the story of how they did it and what they found, broken down into simple concepts:

1. Building the "Heart City" with Highways

The researchers took two separate ingredients:

• The Heart Part: A ball of beating heart cells (a standard heart organoid).
• The Road Part: A ball of blood vessel cells (a blood vessel organoid).

Instead of just mixing them together like a salad, they carefully assembled them side-by-side in a special gel. Over time, something magical happened. The blood vessels didn't just sit next to the heart; they reached out, branched out, and burrowed deep inside the heart tissue, creating a unified, living network.

The Result: A mini-heart that is bigger, healthier, and doesn't have dead cells in the middle because the "roads" deliver oxygen everywhere.

2. The "Growing Up" Effect

When heart cells are surrounded by these new highways, they don't just survive; they mature.

• The Analogy: Imagine a teenager who is stuck in a small town with no opportunities. They stay immature. But if you move them to a bustling metropolis with jobs, schools, and mentors, they grow up fast.
• The Science: The blood vessels sent signals to the heart cells, telling them, "It's time to grow up!" The heart cells started acting more like adult heart cells (17-week fetal stage), beating stronger, handling electricity better, and using energy more efficiently.

3. The Two-Way Street (Crosstalk)

The most exciting discovery is that the relationship isn't just one-way. It's a conversation.

• Heart to Vessel: The heart cells sent out a specific protein (like a letter) called Laminin-α2. This letter told the blood vessels, "You aren't just generic roads; you need to become arteries (the high-pressure highways) specifically for the heart."
• Vessel to Heart: In return, these newly specialized arterial vessels sent back a signal (a molecule called Ephrin-B2) that told the heart cells, "Keep maturing! You're doing great!"

It's like a perfect dance where the heart and the blood vessels teach each other how to be their best selves.

4. Testing a Dangerous Drug (Carfilzomib)

The researchers used this new, advanced model to test a cancer drug called Carfilzomib. This drug is great for treating blood cancer, but it has a nasty side effect: it can cause heart failure.

• The Old Way: When scientists tested this drug on simple, non-vascularized mini-hearts, the hearts didn't react much. The model failed to predict the danger.
• The New Way: When they tested it on the new "Highway Heart," the model screamed "Danger!"
  • The drug caused the heart cells to get stressed out (like a factory running too hot).
  • This stress triggered a panic signal (a protein called ATF4) that made the cells release inflammatory messages (IL8).
  • The blood vessels themselves got damaged, and the whole system started to break down.

The old models missed this because they lacked the complex network of cells that actually causes the damage in real human bodies.

5. The Rescue Mission

Because they understood why the drug was hurting the heart (the stress signal), they tried a fix. They added a "chemical sponge" called 4-PBA.

• This sponge soaks up the stress signals.
• The Outcome: The heart cells stopped panicking, the inflammation went down, and the blood vessels stayed intact. The drug's toxicity was significantly reduced.

Why This Matters

This paper is a game-changer because it gives scientists a realistic simulator for human heart disease.

• Before: We were trying to predict how a car crash would hurt a driver by looking at a drawing of a car.
• Now: We have a crash-test dummy with a real skeleton, muscles, and nervous system.

By building a heart that has its own blood supply and "grows up" properly, scientists can now:

1. Understand how heart diseases really start.
2. Test new drugs to see if they are safe for the heart before they reach patients.
3. Find new ways to protect the heart from toxic treatments.

In short, they built a better "heart in a dish" that finally talks back, grows up, and tells the truth about what's happening inside our bodies.

Technical Summary

1. Problem Statement

Human cardiac organoids (hCOs) derived from pluripotent stem cells are valuable tools for modeling heart development and disease. However, they suffer from a critical limitation: poor vascularization.

• Physiological Constraints: The lack of a functional vascular system restricts nutrient and oxygen diffusion, leading to necrosis and apoptosis in the core of large organoids.
• Maturation Deficits: Without a vascular niche, cardiomyocytes (CMs) fail to achieve advanced functional, metabolic, and structural maturation.
• Modeling Gaps: Existing vascularization strategies often rely on predefined cell mixtures or microfluidic "organ-on-chip" systems that lack natural self-organization or fail to capture the reciprocal influence of the cardiac microenvironment on endothelial identity.
• Drug Toxicity Limitations: Non-vascularized models often fail to recapitulate the complex, multicellular mechanisms of drug-induced cardiotoxicity (e.g., Carfilzomib), which involves interactions between CMs, endothelial cells (ECs), and fibroblasts.

2. Methodology

The authors developed a novel assembly strategy to generate vascularized human cardiac organoids (vhCOs) and employed multi-omics and functional assays to characterize them.

• Organoid Assembly:
  • Components: Generated human cardiac organoids (hCOs) and human blood vessel organoids (hBVOs) separately from hiPSCs.
  • Integration: Assembled day-12 hCOs with day-7 hBVOs in a Collagen I-Matrigel matrix (1:1 ratio).
  • Culture: Cultured in a chemically defined medium (CDM) and RPMI mixture to allow self-organization over 42 days.
• Characterization Techniques:
  • Single-Nucleus Multi-omics: Performed snRNA-seq and snATAC-seq to profile cell types, transcriptional states, and chromatin accessibility.
  • Spatial Analysis: Used whole-mount immunostaining (CD31, cTnT, SOX17, etc.) and 3D reconstruction to visualize vascular networks.
  • Functional Assays:
    • Calcium Imaging: Measured calcium transient amplitudes and decay times.
    • Metabolic Profiling: Used Seahorse extracellular flux analysis to measure mitochondrial respiration (OCR) and ATP production.
    • Electrophysiology: Assessed ion channel expression (e.g., KCNQ1, HCN4).
  • Drug Modeling: Treated vhCOs with Carfilzomib (CFZ), a proteasome inhibitor, to model cardiotoxicity.
  • Intervention: Tested the efficacy of 4-phenylbutyric acid (4-PBA), an ER stress inhibitor, as a rescue agent.
  • Mechanistic Validation: Used ligand-receptor interaction analysis, recombinant protein treatments (LN-221, Ephrin-B2), and gene knockdown/overexpression strategies.

3. Key Contributions

1. Generation of vhCOs: Successfully created unified tissues where hCOs and hBVOs self-organize into a single organoid with extensive, lumenized vascular networks penetrating the cardiac core.
2. Discovery of Bidirectional Crosstalk: Uncovered a reciprocal signaling loop:
   • CM $\to$ EC: CM-derived Laminin-α2 (LAMA2) drives ECs toward an arterial and endocardial identity.
   • EC $\to$ CM: Arterial ECs secrete Ephrin-B2, which binds to EphA4 on CMs, driving CM maturation.
3. Advanced Maturation Model: Demonstrated that vhCOs mimic the cellular composition and maturation state of the human fetal heart at 17 post-conceptional weeks (PCWs), significantly more advanced than non-vascularized hCOs.
4. Mechanism of Cardiotoxicity: Identified that CFZ-induced cardiotoxicity is mediated by ATF4-dependent Endoplasmic Reticulum (ER) stress, leading to IL8-mediated inflammation and mitochondrial dysfunction, a phenotype only visible in the vascularized model.

4. Key Results

A. Generation and Characterization of vhCOs

• Vascular Integration: By day 42, vhCOs displayed branched, CD31+ vascular plexuses penetrating the cTnT+ cardiac tissue.
• Cellular Composition: snRNA-seq revealed ECs comprised 11.4% of vhCOs (vs. 1.3% in hCOs), closely matching the 17-PCW human fetal heart.
• Viability: vhCOs showed significantly reduced core apoptosis compared to hCOs due to improved perfusion.

B. Enhanced Cardiomyocyte Maturation

• Transcriptional State: vhCO-derived CMs aligned with 17-PCW fetal CMs in trajectory analysis and had lower CytoTRACE scores (indicating higher maturity) than hCO-CMs.
• Functional Maturation:
  • Electrophysiology: Upregulated adult isoforms (TNNI3, MYH7, KCNQ1) and downregulated immature markers (HCN4).
  • Calcium Handling: Increased transient amplitude and faster decay; upregulated RYR2 and ATP2A2.
  • Metabolism: Enhanced oxidative phosphorylation, fatty acid metabolism, and mitochondrial respiration (higher basal/maximal OCR and ATP production).

C. Endothelial Specification and Crosstalk

• Organotypic Identity: ECs in vhCOs acquired cardiac-specific markers (LAMB1, MYADM) and shifted from venous to arterial (SOX17+, DLL4+, EFNB2+) and endocardial lineages.
• Laminin-α2 Mechanism: CMs secrete Laminin-α2, which binds integrins on ECs to induce arterial fate. Treating hBVOs with LN-221 recapitulated this arterialization.
• Ephrin-B2 Feedback: Arterial ECs secrete Ephrin-B2, activating EphA4 on CMs. This signaling is essential for CM maturation; recombinant Ephrin-B2 treatment of hCOs improved calcium handling and mitochondrial function.

D. Carfilzomib (CFZ) Cardiotoxicity Modeling

• Differential Sensitivity: CFZ caused significant cell death, DNA damage, and calcium dysregulation in vhCOs but had minimal effect on non-vascularized hCOs.
• Multicellular Response: CFZ disrupted the identity of CMs, ECs, and pericytes simultaneously.
• Molecular Mechanism:
  • CFZ triggered ER stress, activating the eIF2α-ATF4 axis.
  • This led to a shift in fibroblast populations from homeostatic (FB1) to stress-responsive (FB2).
  • IL8 Secretion: ATF4 activation drove the secretion of IL8 (CXCL8), creating a pro-inflammatory environment. This IL8 response was absent in non-vascularized models.
  • Mitochondrial Dysfunction: CFZ caused mtROS accumulation and membrane potential depolarization.
• Rescue: Pretreatment with 4-PBA (an ER stress inhibitor) suppressed ATF4 activation, restored mitochondrial function, reduced IL8 secretion, and rescued vascular integrity and cell viability.

5. Significance

• Physiological Fidelity: vhCOs represent the most physiologically faithful in vitro model of the human heart to date, capturing the 17-PCW developmental stage and the critical role of the vascular niche in tissue maturation.
• Mechanistic Insight: The study elucidates a previously underappreciated bidirectional crosstalk (Laminin-α2 $\leftrightarrow$ Ephrin-B2) that drives both vascular specification and cardiomyocyte maturation.
• Drug Discovery Platform: The model successfully recapitulates complex, vascular-dependent drug toxicities (like CFZ-induced cardiotoxicity) that are missed by 2D cultures or non-vascularized organoids.
• Therapeutic Potential: By identifying the ER stress-IL8 axis as a driver of toxicity, the study suggests 4-PBA as a potential cardioprotective strategy for patients undergoing proteasome inhibitor therapy.
• Future Directions: The authors acknowledge limitations (lack of immune cells, autonomic neurons, and hemodynamic flow) and propose future integration of these elements and microfluidic perfusion to further bridge the gap to adult human physiology.